EXECUTIVE SUMMARY

The Neuroendocrine Tumor Research Foundation (NETRF) is the leading non-profit organization supporting basic, translational and clinical neuroendocrine tumor (NET) research. Our mission is to accelerate scientific discovery that will help create new and more effective therapies for carcinoid, pancreatic, bronchial, and other types of NETs.

Since its founding, NETRF has awarded more than $20 million in research grants to investigators whose work can help provide insight into the causes of NETs and/or lead to improved treatments for our patients. While we have made significant progress the past few years, we still have too few NET investigators and an incomplete understanding of the unique characteristics of these tumors.

 

OBJECTIVE

NETRF is seeking investigators and teams of investigators from around the world, with the tools to study neuroendocrine cancers in new ways. We invite innovative and transformative research proposals in NETs to help bring the field closer to more effective therapies. We are equally interested in basic, translational and clinical research applications, and encourage collaborations between investigators with expertise in different fields. We are very interested in grant proposals from multidisciplinary groups comprised of basic scientists, clinicians, and experts in bioinformatics, bio-nanotechnology, or other relevant disciplines. Proposals that cover promising and potentially transferable mechanisms and/or technologies, which have been applied successfully to other areas of cancer research, are highly desirable, and will be evaluated based on their level of applicability to NETs.

We continue to have an interest in understanding the molecular underpinnings of NETs, and the mechanisms that drive initiation and tumor progression. We seek proposals that suggest innovative ways to study NETs in the absence of conventional models, while we will continue to fund grants that aim to create new or optimize existing experimental models. We invite grants on clinical and adaptive studies, therapeutic sequencing, as well as correlative studies that may build upon existing clinical trials. Other topics of interest include nuclear medicine, theranostics, understanding chemotherapy resistance, new approaches to the early diagnosis of NETs, etc. A variety of state-of-the-art technologies may be utilized.

While we will continue to fund research in pancreatic and gastrointestinal NETs, this year we also invite grants that propose to study typical or atypical lung carcinoids. We have created a fund dedicated exclusively to lung carcinoids and we expect to fund at least one such grant in any of the three programs shown below.

  • Accelerator award, a 4-year grant in the amount of $1,200,000 ($300K/year).
  • Petersen Investigator award, a 2-year grant in the amount of $300,000 ($150K/year).
  • Pilot Project award, a 1-year grant at either $50K or $100K/year.

Please, go to https://proposalcentral.altum.com/ to see each program in more detail, and to apply.

 

ELIGIBILITY

Applicants must have a faculty appointment (assistant professor and above). Applicants must have the skills, knowledge, and resources necessary to carry out the proposed research. An MD, PhD, MD/PhD or equivalent degree is required. Eligible organizations include public or private institutions, such as universities, colleges, hospitals, and laboratories, both domestic and international.

Applications from the biotech or pharmaceutical industry are not eligible.

 

SCOPE

Areas of interest: 

  • Application of existing or new technologies to target NETs
    Designer, nano-based drugs to create targeted therapies/treatments, drug delivery to intended cancer targets identified by the molecules they express, oncolytic viruses/cancer vaccines, nanoparticles that allow therapeutic agents to traverse the body efficiently. 
  • Deciphering the molecular underpinnings of NETs
    Elucidation of basic mechanisms underlying NET initiation, progression, monitoring of NET stages, etc. Understand the mechanistic rules for combinatorial treatments to overcome resistance and avoid toxicity.
  • Cell invasion and metastasis
    Drivers of metastasis, anti-metastasis targets, small non-coding RNAs, adhesion molecules and epithelial-to-mesenchymal transition, metastasis-initiating or cancer stem cells, metastatic organotropism, triggers that stimulate invasive behavior in an indolent tumor.
  • The immune microenvironment
    Cold NETs versus hot NETs, immune effector functions and the metabolic landscape of the tumor microenvironment, novel types of CAR T-cell therapy for solid tumors, adaptation or creation of methodologies to reprogram and activate the immune system, immune-engineering, antibody-drug conjugates.
  • Diagnostics
    Predictive/prognostics clinical markers, biomarkers for metastasis, imaging biomarkers, new approaches to the early diagnosis of NETs, circulating tumor cells/cell free DNA/exosomes (blood, urine etc.).
  • Cancer metabolism
    Understand and manipulate the way neuroendocrine cancer cells process energy in order to survive.
  • New/optimized experimental models:
    Cell lines, 3D cultures/organoids, patient-derived xenografts, etc.
  • Clinical Research
    Clinical and correlative studies that may build upon existing clinical trials, proof-of-concept Phase I clinical trials, adaptive studies, combination and sequencing of therapies.
  • Nuclear medicine, theranostics, imaging
    Evaluation of imaging agents, image-guided surgery or therapies, assessment of imaging systems, new delivery systems, radiomics, individualization, combination.

Organs of interest:

  • NEW THIS YEAR: We have a lung carcinoids fund and expect to fund at least one such grant. We invite grants proposing to work on typical or atypical lung carcinoids. We will not entertain grants proposing to work on SCLC, LCLC, non-SCLC, adenocarcinomas, squamous cell carcinomas, mesotheliomas or poorly differentiated non–small cell lung carcinomas.
  • We continue to have an interest in all aspects of gastroenteropancreatic tumors including sites of metastasis.

 

CRITERIA

Projects that bring together investigators from diverse scientific disciplines are highly encouraged. For team applications, one recipient principal investigator and one recipient institution must be selected.

Candidates must demonstrate a commitment to NET research, and the potential for further development in this area. Please note that prior research in this field is not a prerequisite; in fact, the Foundation wishes to encourage scientists with expertise in other areas to enter the field. Applicants must, however, demonstrate a plan for continuing their research in NETs beyond the award period.

NETRF grantees are required to submit progress and financial reports twice per year and throughout the duration of their grant. The progress reports should summarize research accomplishments and use of the funds for each six-month period. Future funding is contingent upon review of progress and achievement of relevant milestones. Grants will be paid in six-month installments, in US dollars, and following satisfactory review of the progress reports.

Awardees are required to attend and present at the annual NETRF Research Symposium held in the spring each year, in the Boston area, and for the duration of their grant. Applicants should use their NETRF grant to pay for their travel to the NETRF conference.

 

PROCESS

The NETRF RFA employs a 2-step process: the 1st step is the submission of a Competitive Letter of Intent (LOI). The purpose of the LOI is to identify projects with the greatest scientific potential without requiring applicants first to submit a full application. A limited number of applicants whose LOI is deemed most meritorious will move to the 2nd step and will be invited to submit a full proposal.

One LOI / applicant / program may be submitted. An applicant may submit more than one LOIs, as long as the other LOIs are submitted to a different program, and there is no scientific overlap between them.

LOIs should outline research with the potential to transform our understanding of NETs and/or lead to improved treatments and diagnostics for patients. LOIs may focus on any type of NET and may propose basic, translational, or clinical cancer research. Submitted LOIs will be reviewed by the NETRF’s Scientific Advisory Board, comprised of highly respected leaders in the field. Investigators with the most promising and transformative ideas will be invited to submit full applications.

Full applications will be peer-reviewed by both external expert reviewers and by the NETRF’s

Scientific Advisory Board. Members of the Scientific Advisory Board will be recused if investigators from their institutions apply, or if there is another direct or perceived conflict of interest. The review process—including all meeting deliberations, scores and written critiques of applications, as well as other materials provided for the review of applications—is confidential. A confidentiality and conflict of interest statement must be signed by each reviewer. Applicants who wish to make reasonable requests to oppose reviewers may do so, explaining the nature of the conflict of interest.

Applications will be evaluated against five criteria, in accordance with NIH guidelines:

  • Significance
  • Approach
  • Innovation
  • Investigators
  • Environment

A statement of institutional commitment, including any tangible support that the institution is willing to commit to the project, is required.

NETRF’s Board of Directors will select the grant recipients based on:

  • The recommendations of the Scientific Advisory Board
  • Available funds
  • Impact of the research on the mission of NETRF

 

USE OF FUNDS

Awarded funds are directed to the institution. Up to 10% in indirect costs may be requested only for grants over $100K. Funds may be used for personnel salaries, supplies, small equipment, and/or research-related services only. Funds must not be used entirely for salaries and may not be applied to costs covered by other sources. Funds may be used to attend the Annual NETRF Symposium.

 

SHARING RESEARCH RESOURCES

Grant recipients that have created unique research resources using NETRF funds, are required to make them readily available to qualified individuals within the scientific community, after publication. Investigators responding to this funding opportunity must include a sharing research resources plan to address how unique research resources will be shared or explain why sharing is not possible.

Investigators that have created new plasmids or viruses are encouraged to submit them to Addgene.

Investigators that have created new cell lines are required to submit them to ATCC. NETRF will facilitate submission to ATCC.

For any questions regarding our RFA, please email us at This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Learn more and apply on the NETRF website.

Purpose

The purpose of the NANETS YI Award is to encourage scientists at the end of their fellowship who have secured a faculty appointment or scientists beginning their faculty appointment to pursue research focused on neuroendocrine tumors.

Award Sponsor

The 2018 NANETS Young Investigator Award is sponsored by a generous educational grant from Novartis.

Award Term

The NANETS Young Investigator Award (YI) is a one year award and will provide $50,000 in funding, which will be directed to the sponsoring institution.  The YI recipient will be expected to present their findings as a poster or oral presentation at the NANETS Annual Symposium.  At the conclusion of the grant year, the recipient must provide NANETS with a written progress report of the project and a budget reconciliation.

  • Scientific summary of the research project
  • Budget reconciliation
  • Any lessons learned that would be useful to other research scientists
  • Investigator’s future clinical and research plans, especially in regards to the field of neuroendocrine tumors
  • Listing of reference citations for all articles or presentations arising from the recipient’s research project
  • Description of how the YI research grant has impacted recipient’s career

Eligibility

  • Candidates must have a MD, MD/PhD, PhD, DO degree or equivalent
  • Candidates must be in the first 5 years of a faculty appointment (instructor, research scientist or above) in an accredited medical school or other institution in North America
  • Candidates must be a NANETS member
  • Previous recipients of BTSI or NCIS awards are not eligible to apply. 

Selection Criteria

Criteria for selection will include both the research proposal itself and the potential of the individual to make future scientific and/or clinical contributions to the neuroendocrine tumor field. Strong emphasis will be placed on the career development plan and the applicant’s personal statements, as well as the research proposal. The research proposals section should focus on research projects with the potential to directly impact and improve the treatment of patients with neuroendocrine tumors. Appropriate projects would include (but are not limited to) studies of neuroendocrine tumor epidemiology, risk factors, clinical outcomes, novel treatment strategies, and translational research projects with clear clinical significance. The research proposal can include development of a clinical trial and/or correlative studies involving existing clinical trials.

Grant Application

The grant application must have the following components in the order listed: 

Please use only Arial or Times New Roman fonts with a font size of 11. Please produce a single PDF file.

  1. Title page: Applicant Name, Project Title, Institution
  2. Career Development Plan (1-2 pages): written by the mentor and applicant. This should include intramural coursework/seminars, protected time, participation in intramural clinical trials and plans to attend national meetings focused on neuroendocrine tumors.
  3. Personal Statement by the Candidate (1-2 pages): the applicant should include description of any past research projects, evidence of interest in neuroendocrine tumors, and description of how the project will contribute to the future development of the candidate as a clinician and/or investigator in the field of neuroendocrine tumors.
  4. NIH Biosketch of the Applicant (5 page maximum)
  5. NIH Biosketch of the Mentor (5 page maximum)
  6. Letter of Institutional Support (1 page)
  7. Research Plan (no more than 3 pages) containing the following elements
    1. Specific Aims
    2. Background and Significance
    3. Preliminary Data (if available)
    4. Methods
  8. Proposed Budget: The funds can be used to support the salary of the applicant, research costs and/or travel.  Indirect expenses including fringe benefits are capped at 10%.

Review Process

Deadline for submission of the application is July 10, 2017 (11:59 pm PDT) and will be done online.  You must be logged in to access the application. Join or Login now. An email will be sent to confirm your submission was received.  Applications will be reviewed by members of the NANETS Executive Committee, Research Committee and presented to the NANETS Board of Directors for final vote and approval. Notification to the recipient will be made by July 31, 2018, and funds will be dispersed to the sponsoring institution no later than December 31, 2018, and upon receipt of a signed letter of agreement. 

Disclaimer

Funding of this award is subject to the approval and availability of grant funds appropriated to NANETS. Therefore, NANETS reserves the right to alter, the number of investigator awards, terms and allowances.

Apply Now

Purpose

The purpose of the NANETS BTSI Award is to encourage scientists at the end of their fellowship who have secured a faculty appointment or scientists beginning their faculty appointment to pursue research focused on neuroendocrine tumors.

Award Sponsor

The 2018 NANETS Basic/Translational Science Investigator Award is sponsored by the Neuroendocrine Tumor Research Foundation with the generous support of the Margie & Robert E. Petersen Foundation.

Award Term

The NANETS Basic/Translational Science Investigator Award is a two-year award and will provide $50,000 in funding each year, which will be directed to the sponsoring institution. The recipient must provide NANETS with a written progress report of the project and a budget reconciliation bi-annually. At the end of the second calendar year, the progress summary must include the following:

  • Scientific summary of the research project
  • Budget reconciliation
  • Any lessons learned that would be useful to other research scientists
  • Investigator’s future clinical and research plans, especially in regards to the field of neuroendocrine tumors
  • Listing of reference citations for all articles or presentations arising from the recipient’s research project
  • Description of how the BTSI research grant has impacted recipient’s career

Eligibility

  • Candidates must have a MD, MD/PhD, PhD, DO degree or equivalent
  • Candidates must be in the first 5 years of a faculty appointment (instructor, research scientist or above) in an accredited medical school or other institution in North America
  • Candidates must be a NANETS member
  • Previous recipients of BTSI or NCIS awards are not eligible to apply

Selection Criteria

Criteria for selection will include both the research proposal itself and the potential of the individual to make future scientific and/or clinical contributions to the neuroendocrine tumor field. Strong emphasis will be placed on the career development plan and the applicant’s personal statements, as well as the research proposal. The research proposals section should focus on research projects with the potential to directly impact and improve the treatment of patients with neuroendocrine tumors. Appropriate projects would include (but are not limited to) risk factors, clinical outcomes, novel treatment strategies, and translational research projects with clear clinical significance. The research proposal can include the development of a clinical trial and/or correlative studies involving existing clinical trials.

Grant Application

The grant application must have the following components in the order listed:

Please use only Arial or Times New Roman fonts with a font size of 11. Please produce a single PDF file.

  • Title page: Applicant Name, Project Title, Institution
  • Career Development Plan: (1-2 pages) written by the mentor and applicant. This should include intramural coursework/seminars, protected time, participation in intramural clinical trials and plans to attend national meetings focused on neuroendocrine tumors.
  • Personal Statement by the Candidate: (1-2 pages) the applicant should include description of any past research projects, evidence of interest in neuroendocrine tumors, and description of how the project will contribute to the future development of the candidate as a clinician and/or investigator in the field of neuroendocrine tumors.
  • NIH Biosketch of the Applicant (5 page maximum)
  • NIH Biosketch of the Mentor (5 page maximum)
  • Letter of Institutional Support (1 page)
  • Research Plan: (3 page mazimum) containing the following elements
  • Specific Aims
  • Background and Significance
  • Preliminary Data (if available)
  • Methods
  • Proposed Budget: The funds can be used to support the salary of the applicant, research costs and/or travel. Indirect expenses are capped @ 5%

Review Process

Deadline for submission of the application is June 13, 2018, and will be done online. You must be logged in to access the application. Join or Login now. An email will be sent to confirm your submission was received. Applications will be reviewed by members of the NANETS Research Committee and presented to the NANETS Board of Directors for final vote and approval. Notification to the recipient will be made by July 13, 2018 and funds will be dispersed to the sponsoring institution no later than December 31, 2018.

Disclaimer

Funding of this award is subject to the approval and availability of grant funds appropriated to NANETS. Therefore, NANETS reserves the right to alter, the number of investigator awards, terms and allowances.

Apply Now

Purpose

This NANETS Theragonistics Investigator Grant (NTIG) is intended to encourage scientists at the end of their fellowship who have secured a faculty appointment or beginning of their faculty appointment to push forward the boundaries of molecularly targeted radionuclide therapy and diagnostics for patients with neuroendocrine tumors.  Personalized, molecularly targeted Theragnostics requires input from many spheres of human biology including, but not limited to, nuclear physics and chemistry, genetics, proteomics, bioinformatics, epidemiology, and patient-centered outcomes research. NANETS welcomes innovative applications in development of new diagnostic and therapeutic radionuclides, pre-clinical studies of Theragnostics combined with other modalities of treatment, investigator-initiated clinical trials, and studies of health care economics. The NANETS Theragnostics investigator’s focus may be in any basic science, pre-clinical, or clinical arena so long as the approach for conducting the studies includes a supportive, multi-disciplinary environment including a strong mentoring team well versed in Theragnostics. 

The purpose of the NTIG Award is to encourage scientists at the end of their fellowship who have secured a faculty appointment or scientists beginning their faculty appointment to pursue research focused on neuroendocrine tumors.

Award Sponsor

The 2018 NANETS Theragnostics Investigator Grant is sponsored by Advanced Accelerator Applications (AAA).

Award Term

The NANETS Theragnostics Investigator Grant is a two-year award and will provide $50,000 in funding each year, which will be directed to the sponsoring institution. The NTIG recipient will be expected to present their findings as a poster or oral presentation at the NANETS Annual Symposium.  At the conclusion of the first year, the recipient must provide NANETS with a written progress report of the project and a budget reconciliation. At the end of the second calendar year, the progress summary must include the following:

  • Scientific summary of the research project
  • Budget reconciliation
  • Any lessons learned that would be useful to other research scientists
  • Investigator’s future clinical and research plans, especially in regards to the field of neuroendocrine tumors
  • Listing of reference citations for all articles or presentations arising from the recipient’s research project
  • Description of how the NTIG has impacted recipient’s career

Eligibility

  • Candidates must have a MD, MD/PhD, PhD, DO degree or equivalent
  • Candidates must have a faculty appointment (instructor, research scientist or above) in an accredited medical school or other institution in North America
  • Candidates must illustrate that they have a strong mentoring team and are in an appropriately supportive environment to facilitate multispecialty involvement in their research
  • Candidates must have a clear commitment to the advancement of theragnostics in the diagnosis and treatment of NETs
  • Candidates must be a NANETS member
  • Previous recipients of BTSI or NCIS awards are not eligible to apply. 

Selection Criteria

Criteria for selection will include both the research proposal itself and the potential of the individual to make future scientific and/or clinical contributions to the neuroendocrine tumor field. Strong emphasis will be placed on the career development plan and the applicant’s personal statements, as well as the research proposal. The research proposals section should focus on research projects with the potential to directly impact and improve the treatment of patients with neuroendocrine tumors. Appropriate projects include basic, translational or clinical research in the area of theragnostics and NETs.  This includes (but is not limited to) studies of neuroendocrine tumor genetics, physiology, nuclear physics and biology, epidemiology, risk factors, clinical outcomes, novel treatment strategies, and translational research projects with clear clinical significance. The research proposal can include the development of a clinical trial and/or correlative studies involving existing clinical trials.

Grant Application

The grant application must have the following components in the order listed: 

Please use only Arial or Times New Roman fonts with a font size of 11. Please produce a single PDF file.

  1. Title page: Applicant Name, Project Title, Institution
  2. Career Development Plan (1-2 pages): written by the mentor and applicant. This should include intramural coursework/seminars, protected time, participation in intramural clinical trials and plans to attend national meetings focused on neuroendocrine tumors.
  3. Personal Statement by the Candidate (1-2 pages): the applicant should include description of any past research projects, evidence of interest in neuroendocrine tumors, and description of how the project will contribute to the future development of the candidate as a clinician and/or investigator in the field of neuroendocrine tumors, specifically in the area of theragnostics.
  4. NIH Biosketch of the Applicant (5 page maximum)
  5. NIH Biosketch of the Mentor/Mentoring Team (5 page maximum)
  6. Letter of Institutional Support (1 page)
  7. Research Plan (no more than 3 pages) containing the following elements
    1. Specific Aims
    2. Background and Significance
    3. Preliminary Data (if available)
    4. Methods
  8. Proposed Budget: The funds can be used to support the salary of the applicant, research costs and/or travel.  Indirect expenses are capped @ 5%.  This budget should include anticipated travel to the NANETS Annual Symposium to present research findings.

Review Process

Deadline for submission of the application is June 13, 2018 (11:59 pm PDT) and will be done online.  You must be logged in to access the application. Join or Login now. An email will be sent to confirm your submission was received.  Applications will be reviewed by members of the NANETS Review Committee and presented to the NANETS Board of Directors for final vote and approval. Notification to the recipient will be made by July 31, 2018, and funds will be dispersed to the sponsoring institution upon receipt of a signed letter of agreement and no later than December 31, 2018. 

Disclaimer

Funding of this award is subject to the approval and availability of grant funds appropriated to NANETS. Therefore, NANETS reserves the right to alter, the number of investigator awards, terms and allowances.

Apply Now

Grant Name: NANETS Clinical Investigator Scholarship

Sponsoring Organization: NANETS

Deadline: June 13, 2018

Grant Amount: $100,000 over two years

Description: The purpose of the NANETS Clinical Investigator Scholarship is to encourage clinicians at the end of their fellowship who have secured a faculty appointment or beginning of their faculty appointment to pursue a clinical career focused on neuroendocrine tumors. Funds also may be used cover an optional 2-4 week visiting fellowship with a NET expert.

The NANETS Clinical Investigator Scholarship will provide $100,000 total divided over two years. Award funds will be directed to the sponsoring institution. At the conclusion of the award period, the recipient must provide NANETS with a written progress report of the project performed during the award period and a budget reconciliation.

The 2018 NANETS NANETS Clinical Investigator Scholarship is sponsored by IPSEN Biopharmaceuticals in memory of Edda Gomez-Panzani.

Criteria for selection will include both the clinical project itself and the potential of the individual to make future clinical contributions to the neuroendocrine tumor field. Strong emphasis will be placed on the career development plan and the applicant’s personal statements and the mentor’s development plan. The clinical proposal section should focus on a project with the potential to directly impact and improve the treatment of patients with neuroendocrine tumors. Appropriate projects would include (but are not limited to) correlative studies involving existing clinical trials, retrospective studies, a NET database, risk factors and/or any project with a clear clinical significance. If the applicant wishes to participate in the optional visiting fellowship with a NET expert, they should include this in their plan. A list of NET experts willing to host trainees in the US and Europe will be provided upon request.

Eligibility Requirements:

  • Candidates must have a MD, MD/PhD, DO degree or equivalent
  • Candidates must be in the first 5 years of a faculty appointment (instructor or above) in an accredited medical school or other institution in North America (must be on staff at time of award)
  • Candidates must be a NANETS member
  • Previous recipients of BTSI or NCIS awards are not eligible to apply.

Submission Requirements:

The scholarship application must have the following components in the order listed:

Please use only Arial or Times New Roman fonts with a font size of 11. Please produce a single PDF file.

  • Title page: Applicant Name, Project Title, Institution
  • Career Development Plan: (1-2 pages) written by the mentor and applicant. This should include intramural coursework/seminars, involvement in cooperative groups, participation in tumor boards, description of clinical protected time and plans to attend national meetings focused on neuroendocrine tumors.
  • Personal Statement by the Candidate: (1 page) the applicant should include description of any past projects, evidence of interest in neuroendocrine tumors, and description of how the project will contribute to the future development of the candidate as a clinician in the field of neuroendocrine tumors.
  • Mentor Development Plan: (1 page maximum) the mentor should include a description of how they will enhance the applicant’s career opportunities and leadership skills, outline their role in the mentoring relationship and ability to supervise the applicant, explain how they will provide a positive learning environment to include the institutional commitment of support for the mentor’s time.
  • Project Description (2 pages maximum)
  • Letter of Mentor Support (1 page)
  • NIH Biosketch of the Applicant (5 pages maximum)
  • NIH Biosketch of the Mentor (5 pages maximum)
  • Letter of Institutional Support (1 page)
  • Proposed Budget: The funds can be used to support the salary of the applicant, project costs and/or travel. Indirect expenses are capped @ 5%.
  • In addition to the application above, the applicant must fill out an additional 1-page supplemental information sheet and upload it separately as part of the online submission process.

Apply online.